这是一篇来自已证抗体库的有关
人类 EGLN1的综述,是根据9篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合EGLN1 抗体。
EGLN1 同义词: C1orf12; ECYT3; HALAH; HIF-PH2; HIFPH2; HPH-2; HPH2; PHD2; SM20; ZMYND6
艾博抗(上海)贸易有限公司
小鼠 单克隆(366G/76/3) | | 艾博抗(上海)贸易有限公司 EGLN1抗体(Abcam, ab103432)被用于被用于免疫组化在人类样本上浓度为10 ug/ml (图 6a). Medicina (Kaunas) (2022) ncbi |
圣克鲁斯生物技术
小鼠 单克隆(H-8) | - proximity ligation assay; 人类; 1:20; 图 2a
| 圣克鲁斯生物技术 EGLN1抗体(Santa Cruz, sc-271835)被用于被用于proximity ligation assay在人类样本上浓度为1:20 (图 2a). Oncotarget (2017) ncbi |
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D31E11) | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(CST, 4835)被用于被用于免疫印迹基因敲除验证在人类样本上 (图 s10a). Nat Cell Biol (2021) ncbi |
domestic rabbit 单克隆(D31E11) | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 4835s)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 2j). J Clin Invest (2019) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 3293)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 5e). Nat Commun (2016) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling Technology, 3293)被用于被用于免疫印迹在小鼠样本上 (图 1). Skelet Muscle (2016) ncbi |
domestic rabbit 多克隆 | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 3293)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4c). Nat Cell Biol (2016) ncbi |
domestic rabbit 单克隆(D31E11) | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling, 4835)被用于被用于免疫印迹在小鼠样本上 (图 3a). Genes Dev (2014) ncbi |
domestic rabbit 单克隆(D31E11) | | 赛信通(上海)生物试剂有限公司 EGLN1抗体(Cell Signaling Technology, 4835)被用于被用于免疫印迹在小鼠样本上浓度为1:1000. J Bone Miner Res (2014) ncbi |
Provenzano A, Chetta M, De Filpo G, Cantini G, La Barbera A, Nesi G,
et al. Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia. Medicina (Kaunas). 2022;58:
pubmed 出版商
Andrade J, Shi C, Costa A, Choi J, Kim J, Doddaballapur A,
et al. Control of endothelial quiescence by FOXO-regulated metabolites. Nat Cell Biol. 2021;23:413-423
pubmed 出版商
Li L, Kang H, Zhang Q, D Agati V, Al Awqati Q, Lin F. FoxO3 activation in hypoxic tubules prevents chronic kidney disease. J Clin Invest. 2019;129:2374-2389
pubmed 出版商
Kozlova N, Wottawa M, Katschinski D, Kristiansen G, Kietzmann T. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. Oncotarget. 2017;8:9885-9898
pubmed 出版商
Oh E, Kim J, Kim J, Kim S, Lee J, Hong S,
et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nat Commun. 2016;7:13593
pubmed 出版商
Shin J, Nunomiya A, Kitajima Y, Dan T, Miyata T, Nagatomi R. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway. Skelet Muscle. 2016;6:5
pubmed 出版商
Lin A, Li C, Xing Z, Hu Q, Liang K, Han L,
et al. The LINK-A lncRNA activates normoxic HIF1? signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18:213-24
pubmed 出版商
Zheng X, Zhai B, Koivunen P, Shin S, Lu G, Liu J,
et al. Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. Genes Dev. 2014;28:1429-44
pubmed 出版商
Cheng S, Xing W, Pourteymoor S, Mohan S. Conditional disruption of the prolyl hydroxylase domain-containing protein 2 (Phd2) gene defines its key role in skeletal development. J Bone Miner Res. 2014;29:2276-86
pubmed 出版商